Abstract
Glioma is the most common intracranial tumor, accounting for 40%–55% of brain tumor cases. The time of diagnosis affects the prognosis of patients. The application of PET imaging agents, which is a noninvasive method of diagnosis, to glioma has increased rapidly in recent years. 18F fluorothymidine (18F-FLT) is a common PET imaging agent, which is a radioactive thymidine analog and is used to evaluate cell proliferation. This imaging agent can provide more information than that from other imaging examinations and agents during and after the treatment of glioma. In this review, we mainly discuss the present research status of glioma imaging agents in the brain, including the 18F-FLT imaging mechanism; the diagnosis, classification, and identification of recurrence and necrosis; the curative effect evaluation and prognosis of glioma from 18F-FLT; and the relationship between 18F-FLT and Ki-67. Key words: Positron emission tomography; Glioma; 18F-fluoro-thymidine
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
